trend of invasive pneumococcal disease according to serotypes
Maria Jose Galvez Medina1, Angela Ramos Pinedo1, Jose Francisco
Valverde Canovas2, Elia Perez3, Javier Solano1, Mercedes Izquierdo1,
Nurua Echave1 and Marta Inmaculada Hernandez1
Hospital Universitario Fundacion Alcorcon, Alcorcon, MadridSpain,
2Microbiologia, Hospital Universitario Fundacion Alcorcon, Alcorcon,
MadridSpain, 3Unidad de Investigacion, Hospital Universitario Fundacion
Alcorcon, Alcorcon, MadridSpain
To compare epidemiologic,clinical and evolutionary aspects of invasive
pneumococcal disease(IPD) in adults in our setting caused by serotypes
included in13-valent pneumococcal conjugate vaccine (PCV13) compared to
Retrospective study including patients>18years old hospitalized
with IPD 01/2007-12/2015. SPSS 18.0 software.
202 samples of IPD,88 caused by serotypes included in PCV13(46.3%).IPD
caused by these serotypes affected more patients>65(56.8%)and
those who had at least 1comorbidity(68.2%).Most frequent
presentation:uncomplicated community-acquired bacterial pneumonia
(57.1%). :comorbidities of patients with IPD caused by PCV13 serotypes
and evolutionary trend of IPD by serotypes.No statistically significant
differences found with other serotypes or with age,type of
comorbidities or clinical presentation.36% of the patients with IPD by
serotypes included inPCV13 had received the 23Vpolysaccharide
vaccine(PPSV23) which also includes these serotypes.
half of IPDcases were caused by serotypes included inPCV13.No
differences between groups for age,type of comorbidity or clinical
presentation.The vaccination coverage in our setting is low,the
effectiveness of PPSV23 has been limited.There was a decrease in the
incidence rate in both groups from 2011 to 2014. However,there has been
a striking increase in the rate of IPD caused by serotypes not included
in the PCV13.
Image : http://images.aidsmap.com/...